Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment
Authors:
Open Access
- 21 June 2012
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 20 (3) , 338-347
Abstract
Oncolytic viruses hold much promise as novel therapeutic agents that can be combined with conventional therapeutic modalities. Measles virus (MV) is known to enter cells using the signaling lymphocyte activation molecule (SLAM), which is expressed on cells of the immune system. Although human breast cancer cell lines do not express SLAM, we found that a wild-type MV (HL strain) efficiently infected various breast cancer cell lines, causing cell death. Based on this finding, we used reverse genetics to generate a recombinant MV selectively unable to use SLAM (rMV-SLAMblind). The rMV-SLAMblind lacked infectivity for SLAM-positive lymphoid cells, while retaining oncolytic activity against breast cancer cells. We showed that, unlike the MV vaccine strains, rMV-SLAMblind used PVRL4 (polio virus receptor-related 4) as a receptor to infect breast cancer cells and not the ubiquitously expressed CD46. Consistent with this, rMV-SLAMblind infected CD46-positive primary normal human cells at a much-reduced level, whereas a vaccine strain of the Edmonston lineage (rMV-Edmonston) efficiently infected and killed them. The rMV-SLAMblind showed antitumor activity against human breast cancer xenografts in immunodeficient mice. The oncolytic activity of rMV-SLAMblind was significantly greater than that of rMV-Edmonston. To assess the in vivo safety, three monkeys seronegative for MV were inoculated with rMV-SLAMblind, and no clinical symptoms were documented. On the basis of these results, rMV-SLAMblind could be a promising candidate as a novel oncolytic virus for breast cancer treatment.Keywords
This publication has 51 references indexed in Scilit:
- Adherens junction protein nectin-4 is the epithelial receptor for measles virusNature, 2011
- Treatment of metastatic breast cancer: second line and beyondAnnals of Oncology, 2010
- Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell CarriersMolecular Therapy, 2010
- Measles Virus Selectively Blind to Signaling Lymphocytic Activation Molecule (SLAM; CD150) Is Attenuated and Induces Strong Adaptive Immune Responses in Rhesus MonkeysJournal of Virology, 2010
- Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer TherapyMolecular Therapy, 2009
- Measles Viruses Possessing the Polymerase Protein Genes of the Edmonston Vaccine Strain Exhibit Attenuated Gene Expression and Growth in Cultured Cells and SLAM Knock-In MiceJournal of Virology, 2008
- Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell linesAntiviral Research, 2008
- Engineered measles virus as a novel oncolytic therapy against prostate cancerThe Prostate, 2008
- Measles Virus Infects both Polarized Epithelial and Immune Cells by Using Distinctive Receptor-Binding Sites on Its HemagglutininJournal of Virology, 2008
- Nectin4/PRR4, a New Afadin-associated Member of the Nectin Family That Trans-interacts with Nectin1/PRR1 through V Domain InteractionJournal of Biological Chemistry, 2001